Article Sidebar

pdf
Date Published: 16/12/2024
Abstract Views: 18
Views pdf: 7
DOI: https://doi.org/10.51298/vmj.v545i1.12176
Issue
Vol. 545 No. 1 (2024)
Section
Các bài báo
How to Cite
Nguyễn, C. M. (2024). CASE REPORT ON A RARE AND UNPRECEDENTED CLINICAL OCCURRENCE: COEXISTING LUNG CANCER, PULMONARY TUBERCULOSIS WITH MEDIASTINAL LYMPHADENITIS, PULMONARY SCLEROSING PNEUMOCYTOMA SUCCESSFULLY TREATED AT THE NATIONAL LUNG HOSPITAL IN 2024. Vietnam Medical Journal, 545(1). https://doi.org/10.51298/vmj.v545i1.12176

CASE REPORT ON A RARE AND UNPRECEDENTED CLINICAL OCCURRENCE: COEXISTING LUNG CANCER, PULMONARY TUBERCULOSIS WITH MEDIASTINAL LYMPHADENITIS, PULMONARY SCLEROSING PNEUMOCYTOMA SUCCESSFULLY TREATED AT THE NATIONAL LUNG HOSPITAL IN 2024

Công Minh Nguyễn

Main Article Content

Abstract

Co-occurrence of lung cancer and pulmonary tuberculosis is rare in clinical practice, with symptoms often being nonspecific. Treatment is complex due to drug interactions and potential adverse effects. Pulmonary Sclerosing Pneumocytoma is an uncommon condition, with surgical resection being the primary treatment. In this report, we present the case of a 74-year-old female patient admitted with symptoms of cough, weight loss, and persistent chest pain. The patient was preoperatively diagnosed with stage I lung cancer coexisting with pulmonary sclerosing pneumocytoma. Post-surgery, she was also found to have coexisting pulmonary tuberculosis with mediastinal lymph node. Methods: Case report and literature review. Results: The patient was successfully treated with surgery and anti-tuberculosis medication. Conclusion: This is the first reported case in the literature of successful treatment of a patient with coexisting lung cancer, pulmonary tuberculosis with mediastinal lymphadenitis, and pulmonary sclerosing pneumocytoma at the National Lung Hospital.

Article Details

Keywords

Lung cancer, Tuberculosis, Pulmonary Sclerosing Pneumocytoma, Coexisting Lung Cancer and Pulmonary Tuberculosis.

References

Woodard GA, Jones KD, Jablons DM. Lung cancer staging and prognosis. Lung cancer: treatment and research. 2016:47-75.
2. Goldstraw P, Chansky K, Crowley J, et al. The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. Journal of Thoracic Oncology. 2016;11(1):39-51.
3. Bagcchi S. WHO's global tuberculosis report 2022. The Lancet Microbe. 2023;4(1):e20.
4. Katzenstein A-LA, Gmelich JT, Carrington CB. Sclerosing hemangioma of the lung: a clinicopathologic study of 51 cases. The American journal of surgical pathology. 1980;4(4):343-356.
5. Cheng MP, Chakra CNA, Yansouni CP, et al. Risk of active tuberculosis in patients with cancer: a systematic review and metaanalysis. Clinical Infectious Diseases. 2017;64(5):635-644.
6. KOMATSU H, ISHIZUKA Y, YONEDA R. A study of coexistence of bronchogenic carcinoma and active pulmonary tuberculosis. Kekkaku (Tuberculosis). 1981;56(2):49-55.
7. Jurado JO, Alvarez IB, Pasquinelli V, et al. Programmed death (PD)-1: PD-ligand 1/PD-ligand 2 pathway inhibits T cell effector functions during human tuberculosis. The Journal of Immunology. 2008;181(1):116-125.
8. Zhu J. Analysis of the clinical differentiation of pulmonary sclerosing pneumocytoma and lung cancer. Journal of Thoracic Disease. 2017;9(9):2974.
9. Riely GJ, Wood DE, Ettinger DS, et al. Non–Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology. Journal of the National Comprehensive Cancer Network. 2024;22(4):249-274.
10. Otoshi R, Ikeda S, Kaneko T, et al. Treatment Strategies for Non-Small-Cell Lung Cancer with Comorbid Respiratory Disease; Interstitial Pneumonia, Chronic Obstructive Pulmonary Disease, and Tuberculosis. Cancers. 2024;16(9):1734.